3. Best tumor response and PFS.

Variables	n (%)
	Escalation cohort (N=17)						Expansion cohort (N=24)
	50 mg/d (N=3)*	100 mg/d (N=3)	150 mg/d (N=3)	200 mg/d (N=3)	250 mg/d (N=5)		100 mg/d (N=15)	200 mg/d (N=9)
*, Tumor response analysis was based on the full analysis set (FAS); PFS, progress-free survival; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; 95% CI, 95% confidence interval; NR, not reached.
CR	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)
PR	0 (0)	0 (0)	0 (0)	1 (33.3)	0 (0)		1 (6.7)	2 (22.2)
SD	3 (100)	1 (33.3)	2 (66.7)	1 (33.3)	3 (60.0)		10 (66.7)	6 (66.7)
PD	0 (0)	2 (66.7)	1 (33.3)	1 (33.3)	2 (40.0)		4 (26.7)	1 (11.1)
ORR	0 (0)	0 (0)	0 (0)	1 (33.3)	0 (0)		1 (6.7)	2 (22.2)
DCR	3 (100)	1 (33.3)	2 (66.7)	2 (66.7)	3 (60.0)		11 (73.3)	8 (88.9)
PFS (month) [mean (95% CI)]	3.9 (2.1−9.7)						3.8 (1.9−NR)	9.9 (7.4−NR)